NEKTAR THERAPEUTICS: A Comprehensive Review of the 2025 Annual Report

Dive into Nektar Therapeutics' 2025 annual report for key insights into the company's performance and future direction, crucial for investors.

Business Overview

Nektar Therapeutics is a biopharmaceutical company developing new drug candidates for cancer and autoimmune diseases. As a "Non-accelerated filer" and "Smaller reporting company," Nektar follows different public reporting standards than larger firms. While this means less frequent detailed disclosures, it can also signal potential for significant growth. As of June 30, 2025, Nektar's publicly traded shares had a market value of approximately $318 million. By March 11, 2026, the company had about 28.7 million shares of common stock outstanding.

Financial Performance

Nektar navigated a challenging financial landscape in 2025. The company reported total revenue of approximately $55 million, primarily from collaboration agreements and product royalties. This revenue decreased by 15% from the previous year, largely due to the conclusion of certain partnership milestones. Despite cost-cutting measures, Nektar recorded a net loss of $210 million for the year. This loss reflects significant ongoing investment in research and development (R&D) and the costs associated with its strategic restructuring. R&D expenses remained substantial at $180 million, highlighting the company's commitment to advancing its pipeline.

Financial Health

Nektar held $120 million in cash, cash equivalents, and marketable securities as of December 31, 2025. This cash position suggests a spending rate that will require careful financial management and future fundraising. The company primarily funds its operations through issuing new equity and collaboration revenues, keeping its long-term debt relatively low. Nektar's ability to maintain sufficient cash depends heavily on how well it manages operating expenses and secures additional financing.

Management Discussion (MD&A Highlights)

Nektar significantly advanced its multi-year restructuring plans, which began in 2022 and 2023. These plans aimed to streamline operations, cut overhead, and focus resources on key drug candidates. In 2025, the company achieved annualized cost savings of approximately $40 million by reducing its workforce by 15% and consolidating research facilities. While these actions resulted in one-time charges of $15 million during the year, they are expected to improve long-term financial efficiency.

To optimize its portfolio and raise capital without issuing new shares (non-dilutive capital), Nektar sold its royalty interest in a legacy oncology asset to Ampersand Capital Partners and Gannet BioChem in December 2024. This transaction generated $75 million in gross proceeds, primarily used to strengthen the company's cash reserves and fund ongoing R&D.

Product Pipeline Development:

• Rezpegaldesleukin (Rezpeg): Nektar continued to advance Rezpeg, an investigational CD122-preferential IL-2 pathway agonist, in collaboration with Eli Lilly. In 2025, Nektar focused on ongoing Phase 2 studies for various autoimmune conditions, with initial data readouts anticipated in late 2026. Rezpeg represents a significant potential asset for Nektar, targeting a large market.
• NKTR-0165: Nektar continued developing NKTR-0165, a novel small molecule targeting a specific pathway in oncology. The program progressed through preclinical studies, and Nektar aims to submit an Investigational New Drug (IND) application in mid-2026 to initiate Phase 1 clinical trials.

To support its operations and pipeline, Nektar executed a securities purchase agreement with TCG Crossover Fund II LP in 2024, raising $50 million through the sale of pre-funded warrants. Building on this funding strategy, Nektar completed a public offering in February 2026, raising an additional $80 million in gross proceeds by issuing approximately 10 million new shares of common stock. Nektar will use these proceeds for general corporate purposes, including funding ongoing clinical trials and R&D activities, and extending the company's cash runway (the period it can operate with existing funds).

Competitive Position

Nektar operates in a highly competitive biopharmaceutical landscape, especially in oncology and autoimmune diseases. Nektar's competitive edge comes from its proprietary polymer conjugate technology, which it uses to develop new drug candidates with potentially better efficacy and safety profiles. Lead assets like Rezpegaldesleukin aim to meet significant unmet medical needs by targeting specific biological pathways. Nektar protects its innovations through its intellectual property portfolio, including patents and trade secrets.

However, the competitive environment includes large pharmaceutical companies with greater financial resources, established sales and marketing infrastructure, and extensive R&D capabilities. It also includes other smaller biotechnology firms developing similar or alternative therapies. The success of Nektar's pipeline and its ability to secure market share will depend on its ability to demonstrate superior clinical outcomes, obtain regulatory approvals, and effectively commercialize its products, potentially through strategic partnerships.

Risk Factors

Investors should consider several significant risks Nektar faces:

• Clinical Development Risk: The success of Nektar's pipeline, particularly Rezpeg and NKTR-0165, depends heavily on positive clinical trial outcomes and regulatory approvals, which are inherently uncertain.
• Customer Concentration Risk: Over 60% of Nektar's current revenue comes from a few key partners, notably AstraZeneca and UCB Pharma. Changes in these relationships or the performance of partnered products could significantly impact Nektar's financial stability.
• Funding and Liquidity Risk: Given its current cash and spending rate, Nektar will need to raise additional capital within the next 12-18 months to fund operations and advance its pipeline. Future financing may involve further equity dilution or debt, which could impact shareholder value.
• Competition: The biopharmaceutical industry is highly competitive, with numerous companies developing treatments for similar indications. This intense competition could impact Nektar's market share and pricing power.

Future Outlook

Nektar's strategy for the coming year focuses on advancing its lead clinical programs, especially Rezpeg, and carefully managing capital to extend its operational runway. The company aims to achieve key clinical milestones, including initial data readouts for Rezpeg in late 2026 and an IND submission for NKTR-0165 in mid-2026. Nektar also plans to explore additional strategic partnerships to de-risk its pipeline and secure future growth, while continuing to optimize its cost structure. Nektar anticipates its current cash, combined with recent financing proceeds, will fund operations into the latter half of 2026, but it will need further capital after that.